Recommended Topic Related To:

Corlopam

"Dec. 18, 2012 -- People who can't get their high blood pressure down with drugs may be helped by a new procedure that deactivates overactive nerves in the kidneys, a small study shows.

The procedure is already available in Europe and "...

Corlopam

INDICATIONS

Adult Patients: Fenoldopam is indicated for the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function. Transition to oral therapy with another agent can begin at any time after blood pressure is stable during fenoldopam infusion.

Pediatric Patients: Fenoldopam is indicated for the in-hospital, short-term (up to 4 hours) reduction in blood pressure (See CLINICAL PHARMACOLOGY/Pediatric Patients).

DOSAGE AND ADMINISTRATION

Adult Patients: The optimal magnitude and rate of blood pressure reduction in acutely hypertensive patients have not been rigorously determined, but, in general, both delay and too rapid decreases appear undesirable in sick adult patients. An initial fenoldopam dose may be chosen from Tables 2 and 3 in the Clinical Pharmacology Section that produces the desired magnitude and rate of blood pressure reduction in a given clinical situation. Doses below 0.1 mcg/kg/min have very modest effects and appear only marginally useful in this population. In general, as the initial dose increases, there is a greater and more rapid blood pressure reduction. However, lower initial doses (0.03 to 0.1 mcg/kg/min) titrated slowly have been associated with less reflex tachycardia than have higher initial doses ( ≥ 0.3 mcg/kg/min). In clinical trials, doses from 0.01-1.6 mcg/kg/min have been studied. Most of the effect of a given infusion rate is attained in 15 minutes.

Fenoldopam should be administered by continuous intravenous infusion. A bolus dose should not be used.Hypotension and rapid decreases of blood pressure should be avoided. The initial dose should be titrated upward or downward, no more frequently than every 15 minutes (and less frequently as goal pressure is approached) to achieve the desired therapeutic effect. The recommended increments for titration are 0.05 to 0.1 mcg/kg/min.

Use of a calibrated, mechanical infusion pump is recommended for proper control of infusion rate during fenoldopam infusion. In clinical trials, fenoldopam treatment was safely performed without the need for intra-arterial blood pressure monitoring; blood pressure and heart rate were monitored at frequent intervals, typically every 15 minutes. Frequent blood pressure monitoring is recommended.

Fenoldopam infusion can be abruptly discontinued or gradually tapered prior to discontinuation. Oral antihypertensive agents can be added during fenoldopam infusion or following its discontinuation. Patients in controlled clinical trials have received intravenous fenoldopam for as long as 48 hours.

PREPARATION OF INFUSION SOLUTION

WARNING: CONTENTS OF AMPULES MUST BE DILUTED BEFORE INFUSION. EACH AMPULE IS FOR SINGLE USE ONLY.

Dilution

Adult Patients: The fenoldopam injection ampule concentrate must be diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, using the following dilution schedule:

mL of Concentrate (mg of drug) Added to Final Concentration
4 mL (40 mg) 1000 mL 40 mcg/mL
2 mL (20 mg) 500 mL 40 mcg/mL
1 mL (10 mg) 250 mL 40 mcg/mL

The drug dose rate must be individualized according to body weight and according to the desired rapidity and extent of pharmacodynamic effect. Table 5 provides the calculated infusion volume in mL/hour for a range of drug doses and body weights. The infusion should be administered using a calibrated mechanical infusion pump that can accurately and reliably deliver the desired infusion rate.

Infusion Rates

Table 5
FENOLDOPAM ADULT INFUSION RATES (mL/hour)
DRUG DOSAGE FOR ADULTS > 40 KG, USING 40 MCG/ML CONCENTRATION
NOTE: CONCENTRATION IS DIFFERENT FROM PEDIATRIC PATIENTS, TABLE 6.

Body Weight (kg) Infusion Rate
0.025
mcg/kg/min
0.05
mcg/kg/min
0.1
mcg/kg/min
0.2
mcg/kg/min
0.3
mcg/kg/min
  Infusion Rates (mL/hour) of 40 mcg/mL solution
40 1.5 3 6 12 18
50 1.9 3.8 7.5 15 22.5
60 2.3 4.5 9.0 18 27
70 2.6 5.3 10.5 21 31.5
80 3 6 12 24 36
90 3.4 6.8 13.5 27 40.5
100 3.8 7.5 15 30 45
110 4.1 8.3 16.5 33 49.5
120 4.5 9 18 36 54
130 4.9 9.8 19.5 39 58.5
140 5.3 10.5 21 42 63
150 5.6 11.3 22.5 45 67.5

Table 5 (continued)
FENOLDOPAM ADULT INFUSION RATES (mL/hour)
DRUG DOSAGE FOR ADULTS > 40 KG, USING 40 MCG/ML CONCENTRATION
NOTE: CONCENTRATION IS DIFFERENT FROM PEDIATRIC PATIENTS, TABLE 6.

Body Weight (kg) Infusion Rate
0.5
mcg/kg/min
0.8
mcg/kg/min
1
mcg/kg/min
1.2
mcg/kg/min
1.4
mcg/kg/min
1.6
mcg/kg/min
Infusion Rates (mL/hour) of 40 mcg/mL solution
40 30 48 60 72 84 96
50 37.5 60 75 90 105 120
60 45 72 90 108 126 144
70 52.5 84 105 126 147 168
80 60 96 120 144 168 192
90 67.5 108 135 162 189 216
100 75 120 150 180 210 240
110 82.5 132 165 198 231 264
120 90 144 180 216 252 288
130 97.5 156 195 234 273 312
140 105 168 210 252 294 336
150 112.5 180 225 270 315 360

The diluted solution is stable under normal ambient light and temperature conditions for at least 24 hours. Diluted solution that is not used within 24 hours of preparation should be discarded. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter or cloudiness is observed, the drug should be discarded.

Pediatric Patients: Fenoldopam should be administered intravenously to pediatric patients by a continuous infusion pump appropriate for the delivery of low infusion rates. Monitoring of blood pressure should be continuous, usually by way of an intra-arterial line. Heart rate should also be continuously monitored. In the clinical trial, the usual starting dose was 0.2 mcg/kg/min with an effect on MAP evident within 5 minutes. At a constant infusion rate the effect was maximal after 20 to 25 minutes. Increased dosages of up to 0.3 to 0.5 mcg/kg/min every 20 to 30 minutes were generally well tolerated. Tachycardia without further decrease in MAP occurred at dosages greater than 0.8 mcg/kg/min. Upon discontinuation of the fenoldopam infusion after an average of 4 hours of therapy, blood pressure and heart rate returned to near baseline within 30 minutes.

PREPARATION OF INFUSION SOLUTION

WARNING: CONTENTS OF AMPULES MUST BE DILUTED BEFORE INFUSION. EACH AMPULE IS FOR SINGLE USE ONLY.

Dilution

Pediatric Patients

mL of Concentrate (mg of drug) Added to Final Concentration
3 mL (30 mg) 500 mL 60 mcg/mL
1.5 mL (15 mg) 250 mL 60 mcg/mL
0.6 mL (6 mg) 100 mL 60 mcg/mL

Table 6 provides the calculated infusion volume in mL/hour for a range of drug doses and body weights. The infusion should be administered using a calibrated mechanical infusion pump that can accurately and reliably deliver the desired infusion rate. As low flow rates (e.g., < 0.5 mL/hr) may not be practical, and due to volume overload, it may be necessary to increase the concentration of fenoldopam in the infused solutions.

Infusion Rates

Table 6: FENOLDOPAM PEDIATRIC INFUSION RATES (mL/hour)
DRUG DOSAGE FOR CHILDREN BETWEEN 5 AND 70 KG, USING 60 MCG/ML CONCENTRATION
NOTE: CONCENTRATION IS DIFFERENT FROM ADULT PATIENTS, TABLE 5.

Body Weight (kg) Infusion Rate
0.2
mcg/kg/min
0.5
mcg/kg/min
0.8
mcg/kg/min
1
mcg/kg/min
1.2
mcg/kg/min
  Infusion Rates (mL/hr) of 60 mcg/mL solution
5 1 2.5 4 5 6
10 2 5 8 10 12
20 4 10 16 20 24
30 6 15 24 30 36
40 8 20 32 40 48
50 10 25 40 50 60
60 12 30 48 60 72
70 14 35 56 70 84

The diluted solution is stable under normal ambient light and temperature conditions for at least 24 hours. Diluted solution that is not used within 24 hours of preparation should be discarded. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter or cloudiness is observed, the drug should be discarded.

HOW SUPPLIED

List Container Concentration Fill Quantity
2304 Single-dose ampule 10 mg/mL 1 mL one per carton
2304 Single-dose ampule 10 mg/mL 2 mL one per carton

Store at 2 to 30°C (35.6 to 86°F).

ABBOTT LABORATORIES, NORTH CHICAGO, IL 60064, USA. FDA Rev date: 4/1/2004

Last reviewed on RxList: 10/24/2008
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Hypertension

Get tips on handling your hypertension.

advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations